Table 1

Demographics and biochemical profile of the patient cohort used for biomarker discovery
Clinical group
Variable BTC PSC IAC Benign other Healthy
Number 39 10 7 14 22
Female: male 15:24 3:7 0:7 9:5 7:15
Age (yrs) 69 (27–93) 48 (22–76) 64 (43–71) 53 (35–47) 60 (39–78)
Bilirubin (μmol/L) 40 (8–616) 17 (7–457) 12 (5–40) 8 (4–38) ND
CA19-9 (U/mL) 295 (1–145528) 17 (1–4119) 15 (1–52) ND ND
CA19-9 >37 U/mL 30/39 3/10 1/4 ND ND
CRP mg/L (N < 5) 44.4 (1–171) 9.9 (1–194.2) 8.6 (5–35.7) ND ND
ALP (U/L) 577 (138–1925) 195 (98–514) 229 (69–642) ND ND
IgG4 g/L (N < 1.3 g/L) ND ND 1.5 (0.49-2.57) ND ND
WCC (x109/L) 8.2 (3.3-14.8) 6.0 (4.3-15.0)* 7.6 (2.3-9.8) ND ND
Neutrophils (x109/L) 5.9 (2.3-12.0) 3.3 (2.8-13.4)* 4.1 (0.7-5.4) ND ND

BTC, biliary tract cancer; PSC, primary sclerosing cholangitis; IAC, IgG4-associated cholangitis. Benign other group comprises sphincter of Oddi dysfunction, stenosis of the Ampulla of Vater and chronic pancreatitis. CA19-9, carbohydrate antigen 19–9; CRP, C-reactive protein; ALP, alkaline phosphatase; IgG4, immunoglobulin G4; WCC, white cell count. Unless otherwise indicated, values indicate median (with range); ND, not determined; *WCC and neutrophil counts were available for only 6 of the 11 PSC patients.

Sandanayake et al.

Sandanayake et al. BMC Clinical Pathology 2014 14:7   doi:10.1186/1472-6890-14-7

Open Data